Although it is reported that Raloxifene inhibited constitutive STAT3 phosphorylation in pancreatic cancer cell and breast cancer cell-lines, whether it is efficient for Raloxifene to inhibit IL-6/GP130/STAT3 signaling in liver cancer cells and suppress tumor growth in vitro and in vivo is still unknown. Here, STAT3 is linked to breast carcinoma.